{"id":"NCT02446717","sponsor":"AbbVie","briefTitle":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy","officialTitle":"A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 (or ABT-493/ABT-530) With and Without Ribavirin in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Failed a Prior Direct-Acting Antiviral Agent (DAA)-Containing Therapy","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2015-04","primaryCompletion":"2016-12","completion":"2017-01","firstPosted":"2015-05-18","resultsPosted":"2017-09-15","lastUpdate":"2017-09-15"},"enrollment":141,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Hepatitis C","Hepatitis C Virus","HCV","Direct-Acting Antiviral Agent (DAA)-Experienced"],"interventions":[{"type":"DRUG","name":"ABT-493, ABT-530","otherNames":["ABT-493 also known as glecaprevir","ABT-530 also known as pibrentasvir","ABT-493/ABT-530 (ABT-493 coformulated with ABT-267) also known as MAVYRET"]},{"type":"DRUG","name":"ribavirin (RBV)","otherNames":[]},{"type":"DRUG","name":"ABT-493/ABT-530","otherNames":["ABT-493 also known as glecaprevir","ABT-530 also known as pibrentasvir","MAVYRET"]}],"arms":[{"label":"Arm A","type":"EXPERIMENTAL"},{"label":"Arm B","type":"EXPERIMENTAL"},{"label":"Arm C","type":"EXPERIMENTAL"},{"label":"Arm D","type":"EXPERIMENTAL"},{"label":"Arm E","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess the efficacy and safety of ABT-493 and ABT-530 with or without ribavirin (RBV) in participants with chronic hepatitis C virus, (HCV)-infection who previously failed treatment with a direct acting antiviral (DAA)-containing regimen.","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)","timeFrame":"12 weeks after the last actual dose of study drug","effectByArm":[{"arm":"ARM A","deltaMin":100,"sd":null},{"arm":"ARM B","deltaMin":95.5,"sd":null},{"arm":"ARM C","deltaMin":86.4,"sd":null},{"arm":"ARM D","deltaMin":88.6,"sd":null},{"arm":"ARM E","deltaMin":91.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["28128852","31568620","30977945","30923816","30012435"],"seeAlso":["http://rxabbvie.com"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":6},"commonTop":["HEADACHE","FATIGUE","NAUSEA","INSOMNIA","CONSTIPATION"]}}